Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
ORTHO TRI-CYCLEN LO is an oral contraceptive tablet containing a combination of norgestimate and ethinyl estradiol in a triphasic formulation. It is indicated for the prevention of pregnancy in women of reproductive age. The drug works by suppressing ovulation and altering cervical mucus and endometrial environment to prevent fertilization.
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating transitional team focus toward generic defense and line extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Zero linked job postings suggest limited active hiring for this product, reflecting its mature lifecycle stage and approaching LOE. Career opportunities are concentrated in defensive brand management, regulatory compliance, and transition planning rather than growth initiatives.
Worked on ORTHO TRI-CYCLEN LO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.